CY1122822T1 - Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο - Google Patents

Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο

Info

Publication number
CY1122822T1
CY1122822T1 CY20201100223T CY201100223T CY1122822T1 CY 1122822 T1 CY1122822 T1 CY 1122822T1 CY 20201100223 T CY20201100223 T CY 20201100223T CY 201100223 T CY201100223 T CY 201100223T CY 1122822 T1 CY1122822 T1 CY 1122822T1
Authority
CY
Cyprus
Prior art keywords
cycloalkynium
sugars
derivative
derivative sugars
conjugates
Prior art date
Application number
CY20201100223T
Other languages
Greek (el)
English (en)
Inventor
Roberto ADAMO
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1122822T1 publication Critical patent/CY1122822T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20201100223T 2013-01-15 2020-03-13 Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο CY1122822T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300707.5A GB201300707D0 (en) 2013-01-15 2013-01-15 Compounds and processes
PCT/EP2014/050483 WO2014111344A1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Publications (1)

Publication Number Publication Date
CY1122822T1 true CY1122822T1 (el) 2021-05-05

Family

ID=47758014

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100223T CY1122822T1 (el) 2013-01-15 2020-03-13 Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο

Country Status (16)

Country Link
US (2) US11135300B2 (cg-RX-API-DMAC7.html)
EP (1) EP2945641B1 (cg-RX-API-DMAC7.html)
JP (3) JP6719209B2 (cg-RX-API-DMAC7.html)
CN (1) CN105377282B (cg-RX-API-DMAC7.html)
BR (1) BR112015016817B1 (cg-RX-API-DMAC7.html)
CA (1) CA2897348C (cg-RX-API-DMAC7.html)
CY (1) CY1122822T1 (cg-RX-API-DMAC7.html)
DK (1) DK2945641T3 (cg-RX-API-DMAC7.html)
ES (1) ES2774729T3 (cg-RX-API-DMAC7.html)
GB (1) GB201300707D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20200351T1 (cg-RX-API-DMAC7.html)
LT (1) LT2945641T (cg-RX-API-DMAC7.html)
PL (1) PL2945641T3 (cg-RX-API-DMAC7.html)
PT (1) PT2945641T (cg-RX-API-DMAC7.html)
SI (1) SI2945641T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014111344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
US20190054127A1 (en) * 2016-03-04 2019-02-21 Euglena Co., Ltd. Antiviral agent and antiviral food
EP4588521A3 (en) 2016-12-30 2025-10-22 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JP7295571B2 (ja) * 2018-02-05 2023-06-21 国立大学法人 宮崎大学 細胞標識剤及び細胞標識キット
CA3103227A1 (en) 2018-06-14 2019-12-19 Mochida Pharmaceutical Co., Ltd. Novel crosslinked alginic acid
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
EP4200268A4 (en) 2020-08-19 2024-10-16 Vaxcyte, Inc. CARRIER PROTEIN POLYSACCHARIDE CONJUGATION PROCESS
EP4346892A2 (en) * 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2024075506A (ja) * 2022-11-22 2024-06-03 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1777236B8 (en) 2002-03-26 2017-02-22 GlaxoSmithKline Biologicals SA Modified saccharides having improved stability in water for use as a medicament
CN101107010A (zh) 2004-11-01 2008-01-16 布里格海姆妇女医院公司 经修饰的链球菌多糖及其用途
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US8133515B2 (en) * 2007-11-21 2012-03-13 University Of Georgia Research Foundation, Inc. Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
ITVI20090234A1 (it) * 2009-09-25 2011-03-26 Termotecniche Fraccaro S R L Off Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo
CA2785410A1 (en) 2009-12-23 2011-06-30 Carlos F. Barbas, Iii Tyrosine bioconjugation through aqueous ene-like reactions
EP3604264A1 (en) 2010-04-27 2020-02-05 SynAffix B.V. Fused cyclooctyne compounds
WO2012017701A1 (ja) * 2010-08-05 2012-02-09 株式会社ミュージックゲート いびき防止マスク
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CN103347862B (zh) 2010-09-27 2018-07-20 乔治亚大学研究基金公司 包含潜在的1,3-偶极-官能化合物的方法和由此制备的材料
US20120208722A1 (en) 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
DK2721045T3 (en) 2011-06-20 2017-07-24 Radiomedix Inc COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS
HK1200190A1 (en) * 2011-12-01 2015-07-31 安吉奥开米公司 Targeted enzyme compounds and uses thereof
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes

Also Published As

Publication number Publication date
DK2945641T3 (da) 2020-03-09
EP2945641A1 (en) 2015-11-25
SI2945641T1 (sl) 2020-03-31
JP2020114839A (ja) 2020-07-30
US20210268116A1 (en) 2021-09-02
EP2945641B1 (en) 2020-01-01
BR112015016817B1 (pt) 2020-11-10
LT2945641T (lt) 2020-02-25
BR112015016817A8 (pt) 2019-10-29
CA2897348A1 (en) 2014-07-24
JP2016506905A (ja) 2016-03-07
BR112015016817A2 (pt) 2017-07-11
US20160166704A1 (en) 2016-06-16
GB201300707D0 (en) 2013-02-27
CN105377282A (zh) 2016-03-02
US11135300B2 (en) 2021-10-05
US12409231B2 (en) 2025-09-09
JP7036854B2 (ja) 2022-03-15
CA2897348C (en) 2022-09-27
HRP20200351T1 (hr) 2020-06-12
WO2014111344A1 (en) 2014-07-24
CN105377282B (zh) 2020-07-17
JP2019073528A (ja) 2019-05-16
ES2774729T3 (es) 2020-07-22
PT2945641T (pt) 2020-03-26
JP6719209B2 (ja) 2020-07-08
PL2945641T3 (pl) 2020-06-15

Similar Documents

Publication Publication Date Title
CY1122822T1 (el) Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
DK3324980T3 (da) Multimålrettede enkeltenhedskonjugater
DK3579883T3 (da) Pyrrolobenzodiazepin-antistofkonjugater
BR112017005122A2 (pt) derivados tetracíclicos ativos em termos pesticidas com substituintes contendo enxofre.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112015032224A2 (pt) anticorpos anti-fcrh5
BR112017015514A2 (pt) derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
BR112017009454A2 (pt) derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas
BR112017019371A2 (pt) derivados tetracíclicos ativos em termos pesticidas com substituintes contendo enxofre
EA201791359A1 (ru) Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина
BR112017019372A2 (pt) derivados tetracíclicos ativos em termos pesticidas com substituintes contendo enxofre
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
BR112017014064A2 (pt) derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
BR112015019647A2 (pt) criação de perfil de caminho com uso de combinação de hardware e software.
LT3544636T (lt) Pirolobenzodiazepino-antikūno konjugatai
BR112015029754A2 (pt) anticorpos anti-teicoico da parede e conjugados
BR112017028600A2 (pt) derivados policíclicos ativos com substituintes contendo enxofre ativos em termos pesticidas
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
DK3612537T3 (da) Pyrrolobenzodiazepinkonjugater
BR112018000052A2 (pt) derivados policíclicos ativos em termos pesticidas com substituintes contendo enxofre